Notably, patients with mild asthma who were treated with a humanized anti-IL-9 monoclonal antibody (MEDI-528) reported fewer asthma exacerbations and reduced post-exercise FEV1 decline than patients treated with a placebo (91). This evidence concerns the gene IL9 and asthma.